Disclosed is a method of predicting clinical responsiveness to glatiramer acetate therapy in a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis, the method comprising evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-alpha concentration, IL-2 concentration and IFN-gamma concentration, or a combination thereof, in the supernatant of PBMCs derived from the human subject is blood, thereby predicting clinical responsiveness to glatiramer acetate, wherein if the biomarker selected is IL-17 concentration then the human subject is identified as a glatiramer acetate responder if the IL-17 concentration is greater than or equal to 120 pg/ml.
